In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators . Selinexor in combination with pembrolizumab demonstrated promising antitumor activity in patients with mNSCLC . The therapy-related toxic effects were consistent with the prior safety data for both drugs .